DELRAY BEACH, Fla., March 9, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Industrial Vehicles Market is forecast to grow from USD 54.41 billion in 2026 to USD 91.44 billion by 2035 at a CAGR of 5.9%.
Browse 160 market data Tables and 80 Figures spread through 290 Pages and in-depth TOC on 'Industrial Vehicles Market'
Industrial Vehicles Market Size & Forecast:
Industrial Vehicles Market Trends & Insights:
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164686137
The market is propelled by the structural transition toward software-defined vehicles (SDVs) and the emergence of the circular economy. Beyond simple fleet expansion, demand is spiking because modern industrial assets are now viewed as upgradable platforms rather than static hardware. Additionally, technological advancements, including electrification and automation, are further transforming industrial vehicle design and functionality, resulting in supporting the steady growth in the industrial vehicles market.
The aisle truck segment is projected to hold the largest share in terms of value of the industrial vehicles market during the forecast period.
The aisle truck segment is projected to hold the largest share of the industrial vehicles market. The Asia Pacific region dominates the demand for aisle trucks. It is mainly attributed to the factors such as growth in manufacturing and industrial sectors, especially industries like automotive, oil & gas, and energy & utilities. Aisle trucks (reach trucks, VNA turret trucks, and order pickers) are designed for high-density, high-bay warehouse environments, where technical complexity and performance requirements are significantly higher than those of standard forklifts.
Aisle trucks are heavily deployed in e-commerce fulfillment centers and automated distribution hubs, where operational efficiency, throughput requirements are high. Aisle trucks installed in these warehouses and fulfillment centers are premium, whose specifications are different than normal forklifts. These warehouses and distribution centers often procure equipment with telematics, fleet optimization software, and service contracts bundled into the purchase, increasing total contract value.
Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=164686137
Germany is projected to lead the industrial vehicles market in Europe.
During the forecast period, Germany is poised to be the largest market for industrial vehicles in Europe, driven by several key factors. Germany's robust industrial landscape, particularly in manufacturing, automotive, and logistics, drives demand for industrial vehicles. Moreover, major industrial vehicle manufacturers and intralogistics companies, such as Jungheinrich AG, KION Group AG, and Linde Material Handling, are headquartered in Germany, strengthening domestic production and innovation capacity, significantly influencing market growth for industrial vehicles in Germany and Europe. For example, Jungheinrich AG has expanded its automated solutions, introducing advanced automation systems, including autonomous mobile robots and smart forklifts that improve warehouse productivity and safety. Additionally, KION Group AG showcased AI-powered digital twin solutions in collaboration with NVIDIA and Accenture to optimize warehouse automation and vehicle coordination.
Top Companies in Industrial Vehicles Market:
The Top Companies in Industrial Vehicles Market are Toyota Industries Corporation (Japan), KION Group AG (Germany), Mitsubishi Logisnext Co., Ltd (Japan), Jungheinrich AG (Germany), Crown Equipment Corporation (US), and Hyster-Yale Materials Handling, Inc. (US).
Browse Adjacent Market: Automotive and Transportation Market Research Reports & Consulting
Top Reports:
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/industrial-vehicles-market-worth-91-44-billion-by-2035--302707950.html
Bachem hat für das Geschäftsjahr 2025 robuste Zahlen vorgelegt und die durchschnittlichen Analystenschätzungen beim Umsatz wie beim Ergebnis übertroffen. Der Pharmazulieferer setzte 695,1 Millionen Franken um, ein Plus von 14,8 Prozent gegenüber dem Vorjahr; in Lokalwährungen lag das Wachstum sogar bei 19,2 Prozent. Im ersten Halbjahr war das Unternehmen in Lokalwährungen noch um 34 Prozent gewachsen. Unter dem Strich erzielte Bachem einen Reingewinn von 148,8 Millionen Franken und damit knapp 24 Prozent mehr als 2024. Damit lag das Unternehmen rund 30 Millionen Franken über der Konsensschätzung.
Auch auf operativer Ebene legte Bachem zu. Der EBITDA stieg um 21,8 Prozent auf 214,7 Millionen Franken, die Marge verbesserte sich um 1,8 Prozentpunkte auf 30,9 Prozent. Darin enthalten ist allerdings ein positiver Sondereffekt von 16,1 Millionen Franken aus der Standortentwicklung im Sisslerfeld sowie dem Verkauf eines Gebäudes in den USA. Bereinigt lag die EBITDA-Marge bei 28,6 Prozent und damit ungefähr auf Höhe der Markterwartungen. Aktionäre sollen an der Entwicklung teilhaben: Die Divende soll von 0,85 auf 0,90 Franken je Aktie erhöht werden.
Für Gesprächsstoff sorgt der Ausblick. Unter der neuen CEO Anne-Kathrin Stoller rückt Bachem von der bisher kommunizierten Marke eines Umsatzes von mindestens 1 Milliarde Franken ab, die 2026 erreicht werden sollte. Im aktuellen Communiqué wird dieses Mittelfristziel nicht mehr explizit erwähnt. Stattdessen stellt das Unternehmen für das laufende Jahr ein Umsatzwachstum von 35 bis 45 Prozent in Aussicht, was einer Spanne von 938 Millionen bis 1,008 Milliarden Franken entspricht. Schafft Bachem den oberen Rand, wäre die bisherige Zielmarke zwar erreicht – die weniger pointierte Formulierung dürfte aber einige Investoren veranlassen, ihre Erwartungen zu justieren.
Operativ richtet Bachem die Organisation auf weiteres Wachstum aus. 2025 investierte der Konzern 332,6 Millionen Franken über alle Standorte hinweg; im laufenden Jahr sollen die Investitionen auf über 400 Millionen Franken steigen. Hintergrund sind unter anderem mehrere Grossaufträge von Herstellern der stark nachgefragten Medikamenten zur Gewichtsreduktion. Gleichzeitig treibt Bachem den Ausbau neuer Kapazitäten voran: Die erste Bauetappe des Gebäudes K wurde Ende 2025 von der Aufsichtsbehörde Swissmedic inspiziert und freigegeben. Das Unternehmen, das Peptid-basierte Wirkstoffe für Indikationen wie Krebs, Diabetes und Fettleibigkeit liefert und parallel ein Standbein im Bereich Oligonukleotide aufbaut, setzt damit klar auf steigende Nachfrage – auch wenn es bei der kommunikativen Zuspitzung seiner Umsatzziele zurückhaltender geworden ist.
